Cargando…

Emollient prescribing formularies in England and Wales: a cross-sectional study

OBJECTIVE: To identify and compare emollient formularies across all clinical commissioning groups (CCGs) and local health boards (LHBs) in England and Wales. DESIGN: Formularies were retrieved via CCG/LHB websites or Google search (October 2016–February 2017). Data on structure and content were extr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Jonathan P, Boyd, Grace, Quinn, Patrick A, Ridd, Matthew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009537/
https://www.ncbi.nlm.nih.gov/pubmed/29895657
http://dx.doi.org/10.1136/bmjopen-2018-022009
_version_ 1783333408609402880
author Chan, Jonathan P
Boyd, Grace
Quinn, Patrick A
Ridd, Matthew J
author_facet Chan, Jonathan P
Boyd, Grace
Quinn, Patrick A
Ridd, Matthew J
author_sort Chan, Jonathan P
collection PubMed
description OBJECTIVE: To identify and compare emollient formularies across all clinical commissioning groups (CCGs) and local health boards (LHBs) in England and Wales. DESIGN: Formularies were retrieved via CCG/LHB websites or Google search (October 2016–February 2017). Data on structure and content were extracted, and descriptive analyses were undertaken. SETTING: 209 English CCGs and 7 Welsh LHBs. MAIN OUTCOME MEASURES: Number and structure of formularies; number, type and name of emollients and bath additive recommendedandnot recommended; and any rationale given. RESULTS: 102formularies were identified, which named 109 emollients and 24 bath additives. Most were structured in an ‘order of preference’ (63%) and/or formulation (51%) format. Creams and ointments were the most commonly recommended types of emollients, and three ointments were the most commonly recommended specific emollients (71%–79% of formularies). However, there was poor consensus over which emollient should be used first line and 4 out of 10 of the most recommended lotions and creams contained antimicrobials or urea. Patient preference (60%) and/or cost (58%) were the most common reasons given for the recommendations. Of the 82% of formularies that recommend the use of bath additives, 75% did not give any reasons for their recommendation. CONCLUSIONS: Emollient formularies in England and Wales vary widely in their structure, recommendations and rationale. The reasons for such inconsistencies are unclear, risk confusion and make for inequitable regional variation. There is poor justification for multiple different, conflicting formularies.
format Online
Article
Text
id pubmed-6009537
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-60095372018-06-25 Emollient prescribing formularies in England and Wales: a cross-sectional study Chan, Jonathan P Boyd, Grace Quinn, Patrick A Ridd, Matthew J BMJ Open Dermatology OBJECTIVE: To identify and compare emollient formularies across all clinical commissioning groups (CCGs) and local health boards (LHBs) in England and Wales. DESIGN: Formularies were retrieved via CCG/LHB websites or Google search (October 2016–February 2017). Data on structure and content were extracted, and descriptive analyses were undertaken. SETTING: 209 English CCGs and 7 Welsh LHBs. MAIN OUTCOME MEASURES: Number and structure of formularies; number, type and name of emollients and bath additive recommendedandnot recommended; and any rationale given. RESULTS: 102formularies were identified, which named 109 emollients and 24 bath additives. Most were structured in an ‘order of preference’ (63%) and/or formulation (51%) format. Creams and ointments were the most commonly recommended types of emollients, and three ointments were the most commonly recommended specific emollients (71%–79% of formularies). However, there was poor consensus over which emollient should be used first line and 4 out of 10 of the most recommended lotions and creams contained antimicrobials or urea. Patient preference (60%) and/or cost (58%) were the most common reasons given for the recommendations. Of the 82% of formularies that recommend the use of bath additives, 75% did not give any reasons for their recommendation. CONCLUSIONS: Emollient formularies in England and Wales vary widely in their structure, recommendations and rationale. The reasons for such inconsistencies are unclear, risk confusion and make for inequitable regional variation. There is poor justification for multiple different, conflicting formularies. BMJ Publishing Group 2018-06-12 /pmc/articles/PMC6009537/ /pubmed/29895657 http://dx.doi.org/10.1136/bmjopen-2018-022009 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Dermatology
Chan, Jonathan P
Boyd, Grace
Quinn, Patrick A
Ridd, Matthew J
Emollient prescribing formularies in England and Wales: a cross-sectional study
title Emollient prescribing formularies in England and Wales: a cross-sectional study
title_full Emollient prescribing formularies in England and Wales: a cross-sectional study
title_fullStr Emollient prescribing formularies in England and Wales: a cross-sectional study
title_full_unstemmed Emollient prescribing formularies in England and Wales: a cross-sectional study
title_short Emollient prescribing formularies in England and Wales: a cross-sectional study
title_sort emollient prescribing formularies in england and wales: a cross-sectional study
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009537/
https://www.ncbi.nlm.nih.gov/pubmed/29895657
http://dx.doi.org/10.1136/bmjopen-2018-022009
work_keys_str_mv AT chanjonathanp emollientprescribingformulariesinenglandandwalesacrosssectionalstudy
AT boydgrace emollientprescribingformulariesinenglandandwalesacrosssectionalstudy
AT quinnpatricka emollientprescribingformulariesinenglandandwalesacrosssectionalstudy
AT riddmatthewj emollientprescribingformulariesinenglandandwalesacrosssectionalstudy